In the early years of studying immunotherapy at Penn Medicine, our high hopes for an immunological breakthrough in pancreatic cancer were frustrated by the cancer’s unique capacity to resist immune system interventions.
However, new research at Penn’s Abramson Cancer Center is beginning to shed light on the once intractable mechanisms of pancreatic cancer.
In this video, CAR-T pioneer Carl June, MD, explains the innate challenges he encountered when using immunotherapies to treat pancreatic cancer. Dr. June also reviews the potential of anti-tumor mesothelin-specific CAR-T cell therapy in metastatic pancreatic ductal adenocarcinoma (PDA), which is now being investigated through clinical trials at Penn.
Related Links
Pancreatic Cancer: Associated Signs, Symptoms, Risk Factors and Treatment Approaches
CAR-T Cell Therapy: A Breakthrough Treatment for Fighting Cancer
Immunotherapy for Pancreatic CancerImmunology and Immunotherapy for Pancreatic Cancer | A Penn Medicine CME
Enrolling Clinical Trials: Rucaparib for the Treatment of Pancreatic CancerImmunotherapy for Pancreatic Cancer
Enrolling Clinical Trials: Combination Chemotherapy / Immunotherapy for Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Twitter @PennMDForum
Dr. June’s physician profile
Dr. Lee’s physician profile
Dr. Vonderheide’s physician profile
Published
May 22, 2019
Created by
BROADCASTMED